Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Stem cell specialist takes steps forward

by Rick Mullin
May 8, 2017 | A version of this story appeared in Volume 95, Issue 19

Magenta Therapeutics has advanced its stem cell transplantation efforts on three levels. It completed a $50 million series B financing round intended to fuel development of products in areas including patient preparation and stem cell harvesting. It in-licensed a Novartis product, MGTA-456, designed to expand the number of cord blood stem cells used in transplants. And it formed a partnership with Be The Match BioTherapies in which it will use Be The Match’s cell therapy delivery platform, clinical trial design, and industry relationships in research efforts.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.